IV Pulse Cyclophosphamide In Refractory IBD

Below is result for IV Pulse Cyclophosphamide In Refractory IBD in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

Cyclophosphamide Pulse Therapy in Severe Refractory Crohn s

Cyclophosphamide Pulse therapy Refractory Crohn s disease Retrospective multicenter case series Abstract Background and Aims: In Crohn s disease (CD) patients still remain refractory to current regimens, including biologicals. Previous data from small single-center studies indicated cy-

INFLIXIMAB INFUSION ADMINISTRATION AND MANAGEMENT FOR P CROHN

intestinal inflammation. In Inflammatory Bowel Disease, immune cells associated with an overactive immune system produce excess amounts of TNF-α. Controlled trials in patients with refractory Crohn s disease, Fistulising Crohn s disease and ulcerative colitis using the

Therapeutic Management of Pyoderma Gangrenosum

Cyclophosphamide. Recommended dermato-logic doses for treating severe PG are 1,000 mg/week intravenously (IV) for the first 3 weeks, followed by 1 2 mg/kg/day orally in combination with low-dose cortico-steroids (17). Alternatively, the rheumatologic regi-Table 2. Diseases associated with pyoderma gangrenosum* Frequently

Clerkship Lecture 2015 Handout 20151102 [Read-Only]

Adalimumab, Etanercept, Infliximab (IV), et al CTLA4 agonist (inhibit T cell co‐stimulatory process Abatacept anti‐CD20 (B cells) Rituximab anti‐IL1 Anakinra anti‐IL6 Tocilizumab

Roche analyst audio webcast Tuesday, 12 November 2019

Nov 12, 2019 Roche legacy in immunology. 7 1993. 1995 1997. 2003. 2010. 2014 Rheumatoid arthritis Paediatric juvenile idiopathic arthritis Systemic juvenile idiopathic arthritis

RHEUMATOLOGY OVERVIEW

Anti-IL6: tocilizumab in refractory cases Medium vessel vasculitis Steroids, cyclophosphamide when appropriate Treat underlying HBV if present in PAN Small vessel vasculitis Steroids, methotrexate or azathioprine for mild disease Severe disease: Rituximab, cyclophosphamide, plasma exchange

Clerkship Lecture 2015 Handout 20151102

Adalimumab, Etanercept, Infliximab (IV), et al CTLA4 agonist (inhibit T cell co‐stimulatory process Abatacept anti‐CD20 (B cells) Rituximab anti‐IL1 Anakinra anti‐IL6 Tocilizumab

INFLAMMATORY BOWEL DISEASE Safety and efficacy of intravenous

phosphamide pulse therapy was used in refractory IBD patients to evaluate both its efficacy and safety. Methods: Between December 1998 and May 2001, seven patients (Crohn s disease, n=5; indetermi- nate colitis, n=1) with severe steroid refractory IBD (Crohn s disease activity index (CDAI) 264 479

REVIEW IN RHEUMATOLOGY

1997-98 : IV CYC 1999 : Induction with CYC, maintenance MTX 2003 : Induction with CYC, maintenance AZA 2005: MTX up to 25 mg/wk as good as oral CYC in early AAV without critical organ disease 2009: CYCLOPS study: pulse CYC 15 mg/kg q2 -3 weeks = oral CYC 2mg/kg/d plus steroids

RHEUMATOLOGY OVERVIEW

Adalimumab, Etanercept, Infliximab (IV), et al CTLA4 agonist (inhibit T cell co-stimulatory process Abatacept anti-CD20 (B cells) Rituximab anti-IL1 Anakinra anti-IL6 Tocilizumab

Giant Cell Arteritis (GCA) / Temporal Arteritis

o Severe: Cyclophosphamide (2mg/kg/d, can go up to 5mg/kg/d x3d if very ill) o Monitor: UA Qmo forever b/c 50% will relapse after initial remission regardless long-term survival is likely if pts are treated with a disease mortality of only 13% o. Microscopic PolyAngiitis (MPA) (90% renal 50% pulm)